- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07591038
PET/CT Imaging in Carriers of TTR Mutations (EPIC-TTR)
Iodine-124 Evuzamitide PET/CT Imaging in Carriers of TTR Mutations
The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E).
Participants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET/CT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET/CT to make amyloidosis visible in the heart and body.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Amy Browning
- Telefoonnummer: 214-645-8040
- E-mail: Amy.Browning@utsouthwestern.edu
Studie Contact Back-up
- Naam: Jerah Sanchez
- Telefoonnummer: 214-645-7303
- E-mail: jerahmarie.sanchez@utsouthwestern.edu
Studie Locaties
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75248
- UT Southwestern Medical Center
-
Hoofdonderzoeker:
- Justin L Grodin, MD MPH
-
Onderonderzoeker:
- Lori Roth, PA-C
-
Contact:
- Jerah Sanchez
- Telefoonnummer: 214-645-7303
- E-mail: jerahmarie.sanchez@utsouthwestern.edu
-
Onderonderzoeker:
- Vlad Zaha, MD PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
A. Pathogenic TTR Allele Carriers without HF
Inclusion:
- men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)
- have already completed the protocol for NCT05489549 at UT Southwestern only
Exclusion:
- a self-reported history or clinical history of HF
- other known causes of cardiomyopathy
- history of light-chain cardiac amyloidosis
- prior type 1 myocardial infarction
- cardiac transplantation
- liver transplantation
- body weight or habitus that exceeds the site-specific PET/CT parameters
- estimated glomerular filtration rate ≤30 mL/min/1.73 m2
- inability to safely undergo PET/CT
- participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
- pregnancy or breastfeeding
- patients taking heparin or heparin derivatives for anticoagulation
- allergy to potassium iodide
- known uncorrected thyroid disorder
B. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment):
Inclusion:
- men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)
- hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein
- TTR gene sequencing confirming the TTR variant
- have already completed the protocol for NCT05489549 at UT Southwestern only
Exclusion:
- other known causes of cardiomyopathy
- history of light-chain cardiac amyloidosis
- cardiac transplantation
- liver transplantation
- history of type I myocardial infarction
- body weight or habitus that exceeds the site-specific PET/CT parameters
- estimated glomerular filtration rate ≤30 mL/min/1.73 m2
- inability to safely undergo PET/CT
- participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
- patients taking heparin or heparin derivatives for anticoagulation
- pregnancy or breastfeeding
- allergy to potassium iodide
- known uncorrected thyroid disorder
C. Non-carrier race-matched controls:
Inclusion:
- men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician
- have previously enrolled in the Dallas Heart Study
Exclusion:
- a self-reported history or clinical history of HF
- other known causes of cardiomyopathy
- history of light-chain cardiac amyloidosis
- prior type 1 myocardial infarction
- cardiac transplantation
- liver transplantation
- body weight or habitus that exceeds the site-specific PET/CT parameters
- estimated glomerular filtration rate ≤30 mL/min/1.73 m2
- inability to safely undergo PET/CT
- participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
- patients taking heparin or heparin derivatives for anticoagulation
- pregnancy or breastfeeding
- allergy to potassium iodide
- known uncorrected thyroid disorder
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Pathogenic TTR Allele Carriers without Heart Failure
|
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits.
PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging.
Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g.
heart, kidney, spleen).
|
|
Subjects with Symptomatic ATTR-CA
|
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits.
PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging.
Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g.
heart, kidney, spleen).
|
|
Non-carrier race-matched controls
|
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits.
PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging.
Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g.
heart, kidney, spleen).
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
LV % Injected dose
Tijdsspanne: PET/CT Scan Visit
|
Evidence of subclinical cardiac amyloid infiltration as measured by PET/CT quantification imaging with I-124E.
This will be defined as LV % injected dose (LV%ID = volume of interest [VOI] mean activity concentration in the LV X VOI volume / injected activity).
LV%ID is an ideal metric to assess cardiac amyloid burden because it is: 1) correlated with validated metrics assessing cardiac amyloid burden; 2) sensitive for detection of early disease (patchy vs. diffuse uptake); and 3) highly repeatable and standardizable to other metrics of radiotracer uptake.
LV%ID is adjusted for injected activity, but not for body weight, because the latter is unnecessary for a radiotracer accumulating in the heart and specific organs, not in the whole body.
|
PET/CT Scan Visit
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
LVFW SUVR, mean
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
LVFW wall SUVR, max
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
IVS SUVR, mean
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
IVS SUVR, max
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RVFW SUVR, mean
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RVFW SUVR, max
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RV % Injected Dose (RV%ID)
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
LV Cardiac Amyloid Activity (CAA)
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
LV Target-to-Background Ratio (TBR)
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RV Cardiac Amyloid Activity (CAA)
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RV Target-to-Background Ratio (TBR)
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Left Atrial Uptake
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Right Atrial Uptake
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Liver Uptake
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Spleen Uptake
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Kidney Uptake
Tijdsspanne: PET/CT Scan Visit
|
PET/CT Scan Visit
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Justin L Grodin, MD MPH, University of Texas Southwestern Medical Center
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- STU-2026-0286
- R01HL172993 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .